We have created a practical framework to increase sustainable access of our innovative medicines for complex and rare diseases in low- and middle-income countries (LMICs) and delivered through targeted partnerships across the whole patient journey.
Learn more about our position on access.
Takeda’s Access to Medicines approach is centered on patients’ needs. Our programs are focused on strengthening countries’ healthcare systems at every stage of the patient journey.
Our flagship Access to Medicines initiative is the Blueprint for Innovative Healthcare Access. It is an implementation model that is locally integrated to improve the lives of patients by strengthening the entire healthcare system for NCDs.
We aim for earlier diagnosis and local access to consistent high-quality innovative medicines, while enhancing local standards of care.
It is designed to be sustainable by building a local consortium of expert partners, including governments, who drive implementation. It addresses healthcare access barriers through sharing resources, expertise and responsibilities, with strong governance, leadership and coordination.
It starts by fully understanding the local healthcare environment and identifying the healthcare gaps, and it is then applied in a tailored and targeted way with independent measurement across the whole patient journey - from awareness, diagnosis to treatment.
Takeda has also implemented wide-ranging programs across every stage of the patient journey to improve patient lives. We have taken the lessons learned and built on successes to inform our Blueprint approach.
Takeda takes a patient-centric view to the development of our highly-innovative medicines and has developed an end-to-end access approach to make the medicines available as soon as practically possible.
We implement programs that provide patient access throughout the product lifecycle, with a commitment to transition plans for early access programs to ensure appropriate continued access for patients.